VTX-0811
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma[1].
Product Specifications
UNSPSC
12352203
Target
C-Myc; NF-κB; TNF Receptor
Related Pathways
Apoptosis; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
[VTX-0811]
References & Citations
[1]Feldman I, et al. VTX-0811, a first-in-class PSGL-1 blocking monoclonal antibody, repolarizes tumor associated macrophages and induces inflammation in the tumor microenvironment, leading to suppression of tumor growth in pre-clinical studies[J]. Cancer Research, 2022, 82 (12_Supplement) : 5602-5602.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
